Alzheimer's disease, Mild cognitive impairment, mild AD, Plasma biomarkers, Glial fibrillary acidic protein (GFAP), Homocysteine, Metabolic-endocrine dysregulation
schizophrenia, Treatment resistance, clozapine, Plasma proteomics, Immune-metabolic dysregulation, Biomarker signatures.